title: Drug interactions with sunitinib.
abstract: OBJECTIVE
  Sunitinib is a tyrosine kinase inhibitor indicated for the treatment of gastrointestinal stromal tumor, advanced renal cell carcinoma, and pancreatic neuroendocrine tumors. The aim of this article is to describe the pharmacological interactions between sunitinib and commonly prescribed drugs.
  
  
  METHODS
  We reviewed available information on pharmacological interactions between sunitinib and concomitantly prescribed drugs. Drugs were grouped into different therapeutic groups according to the Anatomical Therapeutic Chemical (ATC) classification.
  
  
  RESULTS
  Sunitinib interacts with CYP3A4 inducers or inhibitors and with P-glycoprotein and ABCG2 substrates. Pharmacodynamic interactions with drugs have also been found.
  
  
  CONCLUSIONS
  Current information on drug interactions between sunitinib and other drugs is scarce and most of the times it is difficult to apply to clinical practice. Even so, this difficulty in managing drug interactions should not be a reason to ignore them as they can help to explain intolerances and treatment failures.
authors.affiliation: Hospital Universitario Cruces, Barakaldo, Spain idoia.bilbaomeseguer@osakidetza.net.
authors.forename: Idoia
authors.initials: I
authors.lastname: Bilbao-Meseguer
authors.affiliation: Hospital Universitario Cruces, Barakaldo, Spain.
authors.forename: Begoña San
authors.initials: BS
authors.lastname: Jose
authors.affiliation: Hospital Universitario Marques de Valdecilla, Santander, Spain.
authors.forename: Leocadio R
authors.initials: LR
authors.lastname: Lopez-Gimenez
authors.affiliation: Hospital Universitario Cruces, Barakaldo, Spain.
authors.forename: Maria A
authors.initials: MA
authors.lastname: Gil
authors.affiliation: Hospital Universitario Cruces, Barakaldo, Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Serrano
authors.affiliation: Hospital Universitario Cruces, Barakaldo, Spain.
authors.forename: Mikel
authors.initials: M
authors.lastname: Castaño
authors.affiliation: Hospital Universitario Cruces, Barakaldo, Spain.
authors.forename: Saioa
authors.initials: S
authors.lastname: Sautua
authors.affiliation: Hospital Universitario Cruces, Barakaldo, Spain.
authors.forename: Amaya De
authors.initials: AD
authors.lastname: Basagoiti
authors.affiliation: Hospital Universitario Cruces, Barakaldo, Spain.
authors.forename: Ainhoa
authors.initials: A
authors.lastname: Belaustegui
authors.affiliation: Hospital Universitario Cruces, Barakaldo, Spain.
authors.forename: Beatriz
authors.initials: B
authors.lastname: Baza
authors.affiliation: Hospital Universitario Cruces, Barakaldo, Spain.
authors.forename: Zuriñe
authors.initials: Z
authors.lastname: Baskaran
authors.affiliation: Hospital Universitario Cruces, Barakaldo, Spain.
authors.forename: Alazne
authors.initials: A
authors.lastname: Bustinza
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects; D004347:Drug Interactions; D004359:Drug Therapy, Combination / Q000009:adverse effects; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D010946:Plants, Medicinal / Q000009:adverse effects; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D004164:Diphosphonates; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib
keywords: ABCG2 protein; P-glycoprotein; Sunitinib; cytochrome P-450 enzyme system; drug interactions; herb interactions